TNFRSF17 and plasma cell myeloma: Several CAR-T cell products targeting CD19 or B-cell maturation antigen (BCMA) have been approved by FDA for application in acute lymphoblastic leukemia (ALL), B cell lymphoma and multiple myeloma (MM) (2, 3), respectively.